Inflammatory myositis in systemic lupus erythematosus

Bitencourt, Nicole; Solow, Elizabeth B.; Wright, Tracey; Bermas, Bonnie L.

doi:10.1177/0961203320918021

Cited by 43 publications

(57 citation statements)

References 11 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 One other publication noted a high proportion of anti-SSB/La and anti-RNP positivity. 9 We found a trend towards higher prevalence of these antibodies in our incident myositis cases.…”

Section: Discussionmentioning

confidence: 47%

“…Most of the myositis cases, including all of those with incident myositis, had arthritis as an SLE ACR criteria, although so did three-quarters of the non-myositis SLE patients. The suggestion of arthritis as a factor associated with myositis has been found in two cross-sectional analyses, 1,9 but ours is the first to evaluate this prospectively. We also demonstrated that anti-Smith antibody positivity was common among SLE patients who developed myositis, and this antibody was also present in all our incident myositis cases.…”

Section: Discussionmentioning

confidence: 71%

“…One recently published study similarly found that there was a high proportion of non-Caucasian patients in SLE patients with myositis. 9 Nevertheless, very few other studies have measured race/ethnicity as a risk factor for myositis in SLE, and some only included racially homogenous patient populations. 3,12 Our observation that non-Caucasian patients were more likely to develop myositis, could reflect the known observation that SLE patients of African, Hispanic, and Asian race are more likely to develop multiorgan Raynaud's, ACR criteria, and laboratory results were all ever/never up to the index time for each risk set.…”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…These variables were chosen on the basis of past publications suggesting possible associations of these variables with myositis in SLE, mixed connective tissue disease, and/or overlap syndromes. 1,9 Laboratory testing Our lab performs assays for these antibodies using Euroimmun immunoassay kits (Euroimmun AG, Luebec). 10 All lab tests were assessed at baseline (first visit as of Jan. 2000 or enrolment visit if later than this date) and annually up to the index date of each risk set.…”

Section: Demographic and Clinical Datamentioning

confidence: 99%

See 4 more Smart Citations

Myositis in systemic lupus erythematosus

Cotton

Niaki

Zheng

et al. 2021

Lupus

View full text Add to dashboard Cite

Objectives Myositis is an infrequent feature of SLE and may often be overlooked. We aimed to estimate the incidence of myositis in SLE, and to determine demographic and clinical factors associated with it. Methods Within our lupus cohort, we identified potential myositis cases using the SLICC Damage Index for muscle atrophy or weakness, the SLEDAI-2K item for myositis, and annually measured serum creatinine kinase. Cases were confirmed through chart review. We performed descriptive analyses of prevalent myositis cases as of January 2000. From that point onward, we studies patients without myositis to determine risk of incident myositis, using cohort analyses adjusted for demographic variables (age, sex, race/ethnicity). Results As of January 2000, there were 5 prevalent myositis cases in our SLE cohort. Among 560 SLE patients with a study visit from January 2000 onward, with no history of myositis at baseline, 5 new cases (4 females, 1 male) were identified over an average follow-up of 8.5 years (incidence 1.05 cases per 1000 person-years). There was a higher proportion of Caucasians in the non-myositis group versus myositis group, with a trend for fewer females in the myositis cases. Arthritis, Raynaud’s phenomenon, and anti-Smith antibodies were common pre-existing features, occurring in all incident myositis cases. In Cox regression analyses adjusting for age, race/ethnicity and sex, non-Caucasian patients had a markedly increased risk of developing myositis. Conclusion We found a low incidence of myositis in our SLE cohort. A cluster of variables, particularly non-Caucasian race/ethnicity, arthritis, Raynaud’s phenomenon, and anti-Smith antibodies were associated with risk of developing myositis in SLE. These variables may aid clinicians in identifying SLE patients at highest risk for this important complication.

show abstract

“…14 One other publication noted a high proportion of anti-SSB/La and anti-RNP positivity. 9 We found a trend towards higher prevalence of these antibodies in our incident myositis cases.…”

Section: Discussionmentioning

confidence: 47%

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Demographic and Clinical Datamentioning

confidence: 99%

See 3 more Smart Citations

Myositis in systemic lupus erythematosus

Cotton

Niaki

Zheng

et al. 2021

Lupus

View full text Add to dashboard Cite

show abstract

A Rare Manifestation of a Rare Disease: The Importance of Thinking Outside the Box in a Patient With Complex Dermatomyositis

Milne

Sims

Anderson

et al. 2022

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Prajjwal,

Marsool,

Yadav

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundScleroderma, also referred to as systemic sclerosis, is a multifaceted autoimmune condition characterized by abnormal fibrosis and impaired vascular function. Pathologically, it encompasses the persistent presence of inflammation, abnormal collagen buildup, and restructuring of blood vessels in various organs, resulting in a wide range of clinical symptoms. This review incorporates the most recent scientific literature on scleroderma, with a particular emphasis on its pathophysiology, clinical manifestations, diagnostic approaches, and treatment options.MethodologyA comprehensive investigation was carried out on numerous databases, such as PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar, to collect pertinent studies covering diverse facets of scleroderma research.ResultsScleroderma presents with a range of systemic manifestations, such as interstitial lung disease, gastrointestinal dysmotility, Raynaud's phenomenon, pulmonary arterial hypertension, renal complications, neurological symptoms, and cardiac abnormalities. Serological markers, such as antinuclear antibodies, anti‐centromere antibodies, and anti‐topoisomerase antibodies, are important for classifying diseases and predicting their outcomes.DiscussionThe precise identification of scleroderma is crucial for promptly and correctly implementing effective treatment plans. Treatment approaches aim to improve symptoms, reduce complications, and slow down the progression of the disease. An integrated approach that combines pharmacological agents, including immunosuppressants, endothelin receptor antagonists, and prostanoids, with nonpharmacological interventions such as physical and occupational therapy is essential for maximizing patient care.ConclusionThrough the clarification of existing gaps in knowledge and identification of emerging trends, our goal is to improve the accuracy of diagnosis, enhance the effectiveness of therapeutic interventions, and ultimately enhance the overall quality of life for individuals suffering from scleroderma. Ongoing cooperation and creative research are necessary to advance the field and achieve improved patient outcomes and new therapeutic discoveries.

show abstract

Inflammatory myositis in systemic lupus erythematosus

Cited by 43 publications

References 11 publications

Myositis in systemic lupus erythematosus

Myositis in systemic lupus erythematosus

A Rare Manifestation of a Rare Disease: The Importance of Thinking Outside the Box in a Patient With Complex Dermatomyositis

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Contact Info

Product

Resources

About